{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:38:16Z","timestamp":1791005896241,"version":"4.1.0"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,8,1]]},"DOI":"10.2169\/internalmedicine.1801-23","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T17:10:53Z","timestamp":1704129053000},"page":"2193-2198","source":"Crossref","is-referenced-by-count":11,"title":["Liver Cancer with Overlapping Myasthenia Gravis, Myocarditis, Seronegative Autoimmune Autonomic Ganglionopathy, and Myositis Symptoms Induced by Atezolizumab"],"prefix":"10.2169","volume":"63","author":[{"given":"Ryoko","family":"Shibuya","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risako","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Maesaka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hirosawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Bando","sequence":"additional","affiliation":[{"name":"Department of Surgery, Saiseikai Toyama Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Oshima","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Onoda","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Nukui","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Dougu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Joho","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nakatsuji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1127-1134, 2017.","DOI":"10.1212\/WNL.0000000000004359"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 26: 1052-1061, 2021.","DOI":"10.1002\/onco.13931"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Thakolwiboon S, Karukote A, Wilms H. De novo myasthenia gravis induced by atezolizumab in a patient with urothelial carcinoma. Cureus 11: e5002, 2019.","DOI":"10.7759\/cureus.5002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Pan PC, Haggiagi A. Neurologic immune-related adverse events associated with immune checkpoint inhibition. Curr Oncol Rep 21: 108, 2019.","DOI":"10.1007\/s11912-019-0859-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nakane S, Mukaino A, Higuchi O, et al. Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment. Expert Rev Neurother 18: 953-965, 2018.","DOI":"10.1080\/14737175.2018.1540304"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gao CA, Weber UM, Peixoto AJ, Weiss SA. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. J Immunother Cancer 7: 262, 2019.","DOI":"10.1186\/s40425-019-0748-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tezuka T, Okuzumi S, Nakashima C, et al. Dysautonomia associated with immune checkpoint inhibitors. J Neurol 20: 2023.","DOI":"10.1007\/s00415-023-11667-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tatsumi S, Uryu K, Iwasaki S, Harada H. A case of anti-CRMP5 paraneoplastic neurological syndrome induced by atezolizumab for small cell lung cancer. Intern Med 2020.","DOI":"10.2169\/internalmedicine.4889-20"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yamazoe M, Hatakeyama T, Furukawa K, Kato K, Horiuchi K. Atezolizumab-induced Lambert-Eaton myasthenic syndrome in a patient with small-cell lung cancer. Cureus 15: e33557, 2023.","DOI":"10.7759\/cureus.33557"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Arakawa M, Yamazaki M, Toda Y, et al. Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review. eNeurologicalSci 14: 49-50, 2019.","DOI":"10.1016\/j.ensci.2018.12.001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sebbag E, Psimaras D, Baloglu S, et al. Immune-related cerebellar ataxia: a rare adverse effect of checkpoint inhibitor therapy. J Neuroimmune Pharmacol 17: 377-379, 2022.","DOI":"10.1007\/s11481-021-10026-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Urriola N, Adelstein S. Autoimmune autonomic ganglionopathy: ganglionic acetylcholine receptor autoantibodies. Autoimmun Rev 21: 102988, 2022.","DOI":"10.1016\/j.autrev.2021.102988"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Golden EP, Vernino S. Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances. Clin Auton Res 29: 277-288, 2019.","DOI":"10.1007\/s10286-019-00611-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7: 134, 2019.","DOI":"10.1186\/s40425-019-0617-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7: 319, 2019.","DOI":"10.1186\/s40425-019-0774-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Seki M, Uruha A, Ohnuki Y, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 100: 105-113, 2019.","DOI":"10.1016\/j.jaut.2019.03.005"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sakthivel P, Ramanujam R, Wang XB, Pirskanen R, Lefvert AK. Programmed death-1: from gene to protein in autoimmune human myasthenia gravis. J Neuroimmunol 193: 149-155, 2008.","DOI":"10.1016\/j.jneuroim.2007.09.019"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Iwasa K, Yoshikawa H, Furukawa Y, Yamada M. Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis. J Neuroimmunol 325: 74-78, 2018.","DOI":"10.1016\/j.jneuroim.2018.09.012"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/15\/63_1801-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T23:35:59Z","timestamp":1722641759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/15\/63_1801-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1801-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"article-number":"1801-23"}}